

SPONTAN[®] Expands Patient Access via National Pharmacy Networks

20 May 2025

Highlights

- SPONTAN[®] now available through TerryWhite Chemmart's network of over six hundred pharmacies nationwide
- New barcoded commercial packaging developed to support pharmacy integration and telehealth pathways
- Patients with prescriptions from healthcare professionals can now have them filled at participating pharmacies across Australia
- National pharmacy access milestone achieved for SPONTAN under TGA's Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS)
- Enables collection of 'real-time' patient and prescriber responses to SPONTAN

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") is pleased to announce that SPONTAN[®] is now available through [TerryWhite Chemmart's](#) ("TWC") national pharmacy network, representing a key step in the Company's efforts to expand its patient access infrastructure under its [previously announced partnership with Symbion Pty Ltd.](#)

This achievement represents a pivotal milestone in LTR Pharma's access and readiness strategy, transitioning SPONTAN from limited availability to broader pharmacy availability under regulated pathways. The implementation provides LTR Pharma access to over six hundred pharmacy locations throughout Australia. TerryWhite Chemmart, a subsidiary of EBOS Group alongside Symbion, operates one of the country's largest pharmacy networks and maintains a strong presence in metropolitan and regional areas.

Commercial Packaging

LTR Pharma has developed new commercial packaging for SPONTAN, designed specifically for pharmacy distribution. The packaging incorporates TGA-compliant labelling, patient information materials, and pharmacy-standard barcodes. These barcodes are designed to enable integration with future telehealth platforms, providing patients with a direct and streamlined pathway to healthcare professionals for consultation and prescribing.

Prescription Process

Patients with a prescription for SPONTAN from an authorised healthcare professional can now have their prescriptions filled at any participating [TerryWhite Chemmart](#), [Pharmacy Choice](#), or [healthSAVE](#) pharmacies. Dispensing occurs under the oversight of registered healthcare professionals and operates under the TGA's Special Access Scheme (SAS) and Authorised Prescriber Scheme (APS).

Operational Implementation

Following the January 2025 announcement of LTR Pharma's distribution agreement with Symbion, the companies have completed all key integration milestones, including:

- Integration of inventory management systems
- Implementation of TGA-compliant tracking protocols
- Establishment of product handling procedures
- Completion of pharmacist education and training materials

As part of ongoing pharmacist engagement, LTR Pharma will be presenting at the TerryWhite Chemmart Masterclass during the week of 23 June 2025. This educational session is designed to inform and equip pharmacists across the TerryWhite network with clinical insights and dispensing guidance for SPONTAN under the TGA's Special Access and Authorised Prescriber Schemes.

Real-World Data Collection

The expanded pharmacy rollout enables LTR Pharma to gather valuable real-world data on SPONTAN usage. This data supports the Company's regulatory strategy and preparations for a full commercial launch following regulatory approval in Australia and for the planned US launch of ROXUS in 2026, providing insights into prescribing patterns, patient experience, and market dynamics.

LTR Pharma Executive Chairman, Lee Rodne, said:

"The national rollout of SPONTAN through TerryWhite Chemmart and other pharmacy networks represents the implementation of our Symbion partnership and delivers convenient physical access points for patients across the country. This milestone supports our commitment to improving the availability of SPONTAN across Australia while we progress our regulatory pathway. Patients can now have their SPONTAN prescriptions filled at participating pharmacies nationwide, providing a direct pathway from healthcare professional to pharmacy dispensing."

- ENDS -

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is an emerging pharmaceutical company committed to developing and commercialising innovative therapies that address significant unmet medical needs. The Company is leveraging its proprietary intranasal drug delivery platform to enable rapid, non-invasive treatment options across multiple therapeutic areas.

LTR's lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com